{"disease":{"id":"advanced-digestive-system-neuroendocrine-neoplasm","name":"advanced digestive system neuroendocrine neoplasm"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03375320","title":"Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":298,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03950609","title":"Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02420691","title":"Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}